What is InSphero?
InSphero specializes in the development of advanced 3D cell culture and organ-on-a-chip systems, providing pharmaceutical researchers with human-like microtissues such as liver, tumor, and pancreatic models. These sophisticated biological tools allow for more accurate evaluation of drug efficacy and toxicity, significantly reducing the reliance on traditional animal models. By providing high-throughput, scalable, and physiologically relevant data, InSphero enables biotech firms to accelerate their development pipelines while mitigating the risks associated with late-stage clinical failures. The company's platform is essential for organizations aiming to improve the predictive power of their preclinical studies in an increasingly complex regulatory environment.
How much funding has InSphero raised?
InSphero has raised a total of $36.1M across 5 funding rounds:
Series A
$1.9M
Series B
$2.2M
Series C
$21.1M
Unspecified
$850K
Unspecified
$10M
Series A (2010): $1.9M with participation from Redalpine Venture Partners
Series B (2013): $2.2M, investors not publicly disclosed
Series C (2015): $21.1M, investors not publicly disclosed
Unspecified (2015): $850K, investors not publicly disclosed
Unspecified (2018): $10M backed by Venturelab
Key Investors in InSphero
Redalpine Venture Partners
Redalpine is a thesis-driven venture capital firm with expertise in software and science, established in 2006. They provide strategic and hands-on support to highly technical companies, leveraging a team of scientists and operators to drive innovation.
Venturelab
Venturelab is a leading Swiss organization that supports startups through flagship programs designed to foster entrepreneurship. They provide essential training, fundraising, and business development services to help high-potential startups succeed in the global market.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for InSphero?
With the recent influx of capital, InSphero is well-positioned to scale its operations and expand its footprint in the global life sciences market. The company is expected to focus on enhancing its organ-on-a-chip capabilities, potentially integrating artificial intelligence to further refine its predictive modeling accuracy. As the pharmaceutical industry shifts toward more personalized and precise medicine, InSphero's ability to provide human-relevant data will likely remain a cornerstone of its growth strategy. Future initiatives will likely involve deepening partnerships with major pharmaceutical entities and scaling production to meet the rising demand for high-quality, reproducible 3D tissue models in drug development workflows.
See full InSphero company page
